At medipol our aim is to help people lead healthier lives by delivering affordable and accessible medication to all part of the world and discovering, developing and commercializing innovative medicines that satisfy unmet medical needs. Dosing schedules not well established in children Case reports describe dosage regimens that are effective yet tolerated, such as 12.5 mg PO twice weekly over 2 yr in a child aged 4-6 yr, and 100 mg PO twice weekly over 5 months in a child aged 12 yr; mg/kg dosing not reported Hypersensitivity to chloroquine, 4-aminoquinolones Psoriasis, porphyria, retinal or visual field changes For prevention, may use proguanil concomitantly Shown to cause severe hypoglycemia including loss of consciousness that could be life-threatening in patients treated with or without antidiabetic medications; patients should be warned about risk of hypoglycemia and associated clinical signs and symptoms; patients presenting with clinical symptoms suggestive of hypoglycemia during treatment with chloroquine should have blood glucose level checked and treatment reviewed as necessary Not effective in most areas; CDC recommends mefloquine or atovaquone/proguanil - check CDC traveler information for specific recommendations for region May cause hemolysis in glucose-6 phosphate dehydrogenase (G-6-PD) deficiency; blood monitoring may be needed as hemolytic anemia may occur, in particular in association with other drugs that cause hemolysis Monitor CBC periodically with prolonged therapy Caution with history of auditory damage Caution with hepatic disease, alcoholism, and coadministration with other hepatotoxic drugs May provoke seizures in patients with history of epilepsy Antacids and kaolin reduce chloroquine absorption; separate administration by at least 4 hr Irreversible retinal damage observed in some patients; significant risk factors for retinal damage include daily doses of chloroquine phosphate 2.3 mg/kg of actual body weight, durations of use greater than five years, subnormal glomerular filtration, use of some concomitant drug products such as tamoxifen citrate, and concurrent macular disease A baseline ophthalmological examination should be performed within the first year of initiating therapy; for individuals with significant risk factors, monitoring should include annual examinations; discontinue if ocular toxicity is suspected; patient should be closely observed given that retinal changes (and visual disturbances) may progress even after cessation of therapy In individuals of Asian descent, retinal toxicity may first be noticed outside macula; it is recommended that visual field testing be performed in visual field of central 24 degrees instead of central 10 degrees May exacerbate heart failure Not effective against chloroquine- or hydroxychloroquine-resistant strains of Plasmodium species; information regarding geographic areas where resistance to chloroquine occurs, is available at the Centers for Disease Control and Prevention (gov/malaria) Does not treat hypnozoite liver stage forms of Plasmodium and will therefore not prevent relapses of malaria due to P. ovale; additional treatment with an anti-malarial agent active against these forms, such as an 8-aminoquinoline, is required for the treatment of infections with P. ovale Cases of cardiomyopathy resulting in cardiac failure, in some cases with fatal outcome, reported during long term therapy at high doses; monitor for signs and symptoms of cardiomyopathy and discontinue chloroquine if cardiomyopathy develops; chronic toxicity should be considered when conduction disorders (bundle branch block / atrio-ventricular heart block) diagnosed; if cardiotoxicity suspected, prompt therapy discontinuation may prevent life-threatening complications QT interval prolongation, torsades de pointes, and ventricular arrhythmias reported; risk is greater if chloroquine is administered at high doses; fatal cases reported; use with caution in patients with cardiac disease, a history of ventricular arrhythmias, uncorrected hypokalemia and/or hypomagnesemia, or bradycardia ( There are no adequate and well-controlled studies evaluating the safety and efficacy of chloroquine in pregnant women; usage during pregnancy should be avoided except in prophylaxis or treatment of malaria when benefit outweighs potential risk to fetus Because of the potential for serious adverse reactions in nursing infants from chloroquine, a decision should be made whether to discontinue nursing or to discontinue drug, taking into account potential clinical benefit of drug to mother A: Generally acceptable. Individual plans may vary and formulary information changes. Plaquenil maculopathy treatment Plaquenil kidney problems Does plaquenil cause weight gain Chloroquine resistant malaria map Mg 75 mg base to 250 mg 150 mg base PO once daily, limited to no more than 3.5 to 4 mg/kg/day to minimize retinal toxicity. Chloroquine may be used with quinacrine. †Indicates off-label use Injection 50 mg, 100 mg base as phosphate or sulfate per ml in 2-ml ampoule chloroquine base 150 mg is equivalent to chloroquine sulfate 200 mg or Chloroquine phosphate 250 mg General information Policy regarding the use of this drug as an antimalarial must be determined nationally since in many areas P. falciparum is now resistant to chloroquine. Chloroquine phosphate is in a class of drugs called antimalarials and amebicides. It is used to prevent and treat malaria. It is also used to treat amebiasis. This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information. D: Use in LIFE-THREATENING emergencies when no safer drug available. Controlled studies in pregnant women show no evidence of fetal risk. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. Animal studies show risk and human studies not available or neither animal nor human studies done. Contact the applicable plan provider for the most current information. Chloroquine phosphate tablets ip 250 mg uses Chloroquine Phosphate Tablets IP 250mg - Medipol., WHO Model Prescribing Information Drugs Used in Parasitic. Aralen mechanism of actionCan you take plaquenil and unithroidIs plaquenil used to treat fibromyalgia Each 250 mg tablet of chloroquine phosphate is equivalent to 150 mg base. For malaria suppression Adult Dose 500 mg = 300 mg base on exactly the same day of each week. Chloroquine Phosphate Tablets - Chloroquine Phosphate Oral.. Chloroquine MedlinePlus Drug Information. Antimalarial Drugs - Chloroquine Phosphate Tablets 250 mg.. Non-chloroquine-resistant. 1 g 600 mg base PO, THEN; 500 mg 300 mg base PO 6-8 hours later, THEN; 500 mg 300 mg base PO at 24 hours & 48 hours after initial dose; Amebiasis, Extraintestinal. 1 g 600 mg base PO qDay for 2 days, THEN. 500 mg 300 mg base qDay for 14-21 days. Porphyria Cutanea Tarda Off-label 125-250 mg 75-150 mg base PO twice weekly. Glioblastoma Orphan Concomitant use of cimetidine should be avoided. Chloroquine phosphate is calculated as the base. Each 250 mg tablet of chloroquine phosphate is equivalent to 150 mg base and each 500 mg tablet of chloroquine phosphate is equivalent to 300 mg base. One tablet of 200 mg of hydroxychloroquine is equivalent to 155 mg base. In most cases, 250 mg tablets have an equivalence of 150 mg chloroquine base, and 500 mg tablets have an equivalence of 300 mg chloroquine base. Although the purity mentioned above is generally accurate, it would be best to verify the chloroquine base contained in the tablets of your choice in order to be able to properly calculate the exact dosage.